Safety and Efficacy of Intravenous Immune Globulin 10% (BIVIGAM®) in Children with Primary Immune Deficiency

Safety and Efficacy of Intravenous Immune Globulin 10% (BIVIGAM^®) in Children with Primary Immune Deficiency

J Clin Immunol. 2025 Jun 11;45(1):105. doi: 10.1007/s10875-025-01891-1.

Isaac Melamed¹, Jolan E Walter^{2

3

4}, Oral Alpan⁵; BIVI 994 Authors; Jennifer W Leiding^{6

7

8}

BIVI 994 Authors:
Devi Jhaveri, Alan Koterba, Rebecca Avila, Miranda Anaya, Marie-Chantale Simard, Wei Du

¹ IMMUNOe International Research, Centennial, CO, USA.
² Department of Pediatrics, Division of Allergy & Immunology, University of South Florida, Tampa, FL, USA.
³ Department of Pediatrics, Division of Allergy & Immunology, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA.
⁴ Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA.
⁵ Lysosomal Rare Disorders Research and Treatment Center, Fairfax, VA, USA.
⁶ Department of Pediatrics, Division of Allergy and Immunology, Johns Hopkins University, Baltimore, MD, USA. jleidin1@jhmi.edu.
⁷ Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA. jleidin1@jhmi.edu.
⁸ Institute for Clinical and Translational Research, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA. jleidin1@jhmi.edu.

No abstract available

Keywords: Clinical trial; Efficacy; Immune globulin replacement therapy; Intravenous immune globulin; Pediatric population; Safety.